
    
      The maximum study duration per patient will be approximately 31 weeks: an up-to 6-week
      screening and run-in period (with an up-to 2-week screening phase and a 4-week run-in phase),
      followed by a 24-week randomized treatment period and a 3-day post-treatment safety follow up
      period.
    
  